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Current studies suggest that short-term exposure of
parathyroid glands to fibroblast growth factor 23 (FGF23)
reduces parathyroid hormone secretion. However, patients
with chronic kidney disease (CKD) develop secondary hyper-
parathyroidism despite high levels of serum FGF23, indicating
a parathyroid FGF23 ‘resistance’. Here we analyzed the
expression of the FGF23 receptors Klotho and FGF receptor 1
(FGFR1) in 88 hyperplastic parathyroid glands from 31 patients
with CKD (including 21 renal allograft recipients), and their
regulation in isolated bovine and human hyperplastic
parathyroid cells. Glandular expression was variable, yet the
Klotho and FGFR1 mRNA levels declined in parallel with the
decreasing glomerular filtration rate, significantly decreasing
over CKD stages. We found no association between the
expression of Klotho, FGFR1, and the proliferation marker Ki67.
In vitro treatment of bovine cells with FGF23 or calcium
reduced the Klotho level, whereas active vitamin D3 com-
pounds increased its expression. Phosphate and parathyroid
hormone had no effect. Treatment had less impact on Klotho in
cultured human cells than in the bovine healthy cell model,
whereas FGFR1 expression was induced in the hyperplastic
cells. Thus parathyroid Klotho and FGFR1 decrease with dec-
lining renal function, possibly because of alterations in mineral
metabolism related to the failing kidney. This could explain the
observed parathyroid resistance to FGF23 in late CKD.
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Type I membrane-bound a-Klotho (Klotho) has a critical
role in extracellular calcium regulation and is expressed at
high levels in parathyroid glands and kidneys.1,2 It is essential
for the release of parathyroid hormone (PTH) at hypocal-
cemic conditions. In a setting of low extracellular calcium,
Klotho recruits Naþ /Kþ ATPases to the parathyroid
cell membrane and leads to enhanced PTH secretion.3
Klotho further stimulates tubular calcium reabsorption
through glycosylation and anchoring of the calcium-
transporting channel, transient receptor potential ion V5,
to the cell surface.4
Klotho is also a cofactor that converts fibroblast growth
factor-receptor 1 (FGFR1) into a specific receptor for
FGF23,5,6 a bone-derived circulating peptide that regulates
serum inorganic phosphate (Pi) and 1,25-dihydroxy-
vitamin D3 (1,25(OH)2D3) levels.
7–9 We along with
others, previously showed that FGF23 directly suppresses
PTH mRNA level and protein secretion in vitro10 and
in vivo.11
The diminished renal capacity of chronic kidney disease
(CKD) patients to produce 1,25(OH)2D3, and the presence of
hyperphosphatemia due to decreased Pi clearance, are major
causatives of PTH hypersecretion and parathyroid gland
hyperplasia.12 Importantly, CKD patients inevitably develop
secondary hyperparathyroidism (sHPT) despite concomi-
tantly high circulatory FGF23 levels.13 The postponement of
hyperphosphatemia by FGF23 presumably occurs at the
expense of accentuated 1,25(OH)2D3 deficiency,
14 however,
the markedly elevated FGF23 levels also indicate parathyroid
and possibly other end-organ15 resistance. A possible
mechanism could be downregulation of the receptors
mediating FGF23 signaling.15 Herein, we evaluated the
parathyroid expression of FGF-receptors Klotho and FGFR1
in hyperparathyroid CKD patients and kidney transplant
recipients.
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RESULTS
Glandular Klotho mRNA levels
Klotho mRNA expression level in 88 secondary hyperplastic
parathyroid glands showed a large interglandular variation
(Figure 1). We found no association between Klotho
expression and glandular weight (data not shown), or any
difference in Klotho mRNA levels because of the treatment
with active vitamin D3 derivatives (Figure 1). Klotho levels
did not differ between transplanted and non-transplanted
patients, but were generally decreased compared with that in
normal parathyroid tissue (Figure 1).
Nodularity and protein levels of Klotho, Ki67, and
vitamin D3 receptor (VDR)
The majority (67%) of all analyzed glands were of nodular
type. Immunohistochemical (IHC) analysis revealed varying
intensity and heterogeneous intraglandular distribution of
Klotho (Figure 2a, A–B). Only a weak tendency toward lower
Klotho expression in nodular, as compared with diffuse,
hyperplasias was observed with whole-section scoring.
Occasionally, Klotho expression was equal both outside
and within a nodule (Figure 2a, G–H). Thus, there is no
compelling evidence of lower Klotho protein expression in
nodules. Klotho mRNA and protein levels tended to correlate
positively (n¼ 42; Figure 2b). We observed a trend of higher
Ki67 scores in nodular glands (data not shown). Repeated
analysis of whole sections showed no conclusive relation
between Klotho and Ki67 protein levels, nor was statistical
significance reached when applying correlation analysis to the
IHC scores. Figure 2a, C–D illustrates the typically small
number of Ki67-expressing cells. Protein levels of VDR
mainly correlated to Klotho levels (Figure 2a, E, K–L).
Klotho in relation to renal function
Glomerular filtration rate (GFR) was higher in transplanted
patients than in non-transplanted patients (30.2±17.7 versus
9.64±3.80, Po0.01). Mean Klotho levels correlated posi-
tively with log GFR (n¼ 31; r¼ 0.42; Po0.05; Figure 3a) and
the correlation was stronger in the transplanted group
(data not shown). Accordingly, the glandular Klotho mRNA
levels decreased with increasing CKD stages (Po0.05;
Figure 3b).
Klotho in relation to serum biochemistry
Patients’ serum biochemistry parameters are shown in
Table 1. According to the defined cutoffs of 2.5 and
1.5mmol/l, 27 patients suffered from hypercalcemia
(2.76±0.16mmol/l), and 13 from hyperphosphatemia
(2.14±0.79mmol/l), respectively. Univariate correlation
analysis revealed a negative association between serum Pi
and mean Klotho mRNA levels (n¼ 29, r¼0.44, Po0.05;
Figure 3c). The correlation was somewhat stronger
in transplanted patients (n¼ 20, r¼0.57, Po0.01). No
association was observed between mean Klotho mRNA and
serum calcium or PTH levels, not even after stratification for
kidney transplantation (data not shown).
FGFR1 in relation to renal function, Klotho, and serum
biochemistry
Mean FGFR1 mRNA levels did not differ between trans-
planted and non-transplanted patients (data not shown).
A positive correlation was observed between mean FGFR1
and log GFR levels (Figure 4a left), and FGFR1 expression
decreased across CKD stages (Po0.01; Figure 4a middle).
FGFR1 and Klotho mRNA levels correlated positively (Figure
4a right). Mean FGFR1 correlated negatively with serum Pi
(Figure 4b left), and log serum PTH levels (Figure 4b right).
No association existed between mean FGFR1 and serum
calcium levels (data not shown).
Regulation of Klotho expression in cultured bovine
parathyroid cells
To further explore the regulation of parathyroid Klotho
expression, we performed cell culture experiments using
isolated bovine parathyroid cells. We previously showed that
calcium treatment suppressed parathyroid Klotho mRNA
level.16 Treatment with up to 107mol/l of 1,25(OH)2D3 or
with the vitamin D3 analog EB1089 dose dependently
increased the Klotho mRNA level at 24 h (Po0.01,
Figure 5a). On the contrary, FGF23(R176Q) treatment
decreased the Klotho level (Po0.01; Figure 5b). Cotreatment
with EB1089 and FGF23(R176Q) resulted not only in
blunting of the EB1089 effect (Po0.001), but also in a
decreased Klotho expression in compared with control-
treated cells (Po0.001) (Figure 5c). Addition of EB1089,
however, did not mitigate the FGF23(R176Q)-induced
suppression of Klotho (P40.05; Figure 5c). Cotreatment
with FGF23(R176Q) and calcium caused a further suppres-
sion of Klotho mRNA levels as compared with the
FGF23(R176Q) treatment alone (Po0.01; Figure 5c). There
was no additive effect on Klotho mRNA suppression after
treatment with FGF23(R176Q) and calcium, compared with
calcium alone (P40.05; Figure 5c). Combination treatment
with FGF23(R176Q), calcium, and EB1089 resulted in a net
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Figure 1 |Distribution of 88 glandular Klotho mRNA levels.
Klotho mRNA levels in hyperplastic glands from 31 patients and
7 normal parathyroid tissues are depicted. Patients are
categorized on the basis of kidney transplantation and active
vitamin D3 compound treatment (þD). GAPDH, glyceraldehyde
3-phosphate dehydrogenase; LL, lower left; LR, lower right;
Norm, normal; UL, upper left; UK, unknown glandular localization;
UR, upper right.
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Klotho mRNA suppression of magnitude similar to that with
FGF23(R176Q) and calcium (Figure 5c). Finally, we observed
no effect on Klotho transcript level after treatment with
either Pi or PTH (data not shown).
Regulation of Klotho expression in cultured hyperplastic
parathyroid cells from a CKD patient
Calcium was the only single agent that exerted an inhibitory
effect on the Klotho transcript level after 24 h treatment
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Figure 2 |Klotho, Ki67, and vitamin D3 receptor (VDR) protein levels. (a) Representative tumor sections from two patients are depicted
(A–E and G–L). Immunostaining of Klotho/Ki67/VDR is presented in the left/middle/right columns, respectively, and the rows represent the
different magnifications (row 1/2/3/4: 20/40/10/20). Heterogeneous staining of Klotho protein in the two nodules of the first tumor
(A–B) indicates large intraglandular differences. The staining of the second tumor confirms that, regardless of nodular borders, the overall
expression of Klotho is irregular (G–H). There was no association between Ki67 and Klotho expression exemplified by the nodular Ki67
staining (I–J), and the more diffuse Klotho expression (G–H). VDR levels mainly parallel the levels of Klotho (E, K–L). Negative control is shown
in F ( 20 magnification). (b) Klotho mRNA and protein levels tended to correlate positively (n¼ 42). GAPDH, glyceraldehyde
3-phosphate dehydrogenase; IHC, immunohistochemistry.
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of hyperplastic parathyroid cells in vitro (Po0.05; Figure 6a).
The inhibition by FGF23(R176Q) treatment did not reach
the threshold of statistical significance (Figure 6a), however,
the presence of FGF23(R176Q) mitigated the calcium-
induced suppression of Klotho (Po0.05; Figure 6a). Neither
EB1089, 1,25(OH)2D3 (Figure 6a) nor Pi (data not shown)
had any regulative effects on Klotho expression (P40.05).
Treatment with a combination of calcium, EB1089, and
FGF23(R176Q) was the only treatment besides calcium that
had a suppressive effect on Klotho as compared with control
treatment (Po0.05; Figure 6a), and the resulting suppression
was slightly stronger than the one induced by combined
calcium and FGF23(R176Q) treatment (Po0.05), or EB1089
and FGF23(R176Q) treatment (Po0.01) (Figure 6a).
Regulation of FGFR1 expression in cultured hyperplastic
parathyroid cells from a CKD patient
FGFR1 mRNA level was stimulated by 24 h treatment with
FGF23(R176Q), 1,25(OH)2D3, and Pi (Po0.05), whereas
calcium and EB1089 had no significant effects (P40.05)
(Figure 6b). Addition of either calcium (Po0.05) or EB1089
(Po0.001) to FGF23(R176Q)-containing treatment media
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Figure 3 |Klotho expression in relation to renal function and
serum biochemistry. (a) Glomerular filtration rate (GFR) values were
calculated according to the Cockcroft–Gault formula: GFR (ml/min
per 1.73 m2)¼ (140 – age; yrs) (weight; kg) (0.85; if female)/
(72 creatinine; mg/dl). A positive correlation between mean
parathyroid Klotho mRNA levels and log GFR was observed (n¼ 31;
r¼ 0.42; Po0.05). (b) This was supported by a decline in glandular
Klotho mRNA levels over chronic kidney disease (CKD) stages
(n¼ 3/32/14/39, ***Po0.001 versus stage 3). Error bars represent
the 5th and 95th percentiles, and outliers are represented by dots.
(c) Mean Klotho mRNA levels correlated negatively with serum
inorganic phosphate (Pi) (n¼ 29, r¼0.44, Po0.05). Gray dots
represent the four patients from whom only one gland was available
(if these are excluded: n¼ 25, r¼0.54, Po0.01). GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
Table 1 | Patient characteristics
sHPT
Reference
range
No. of patients; glands 31; 88
No. of glands removed
(no. of patients)
1 (4); 2 (7); 3 (10); 4 (10)
CKD stage (no. of
patients; glands)
1 (0; 0); 2 (1; 3); 3 (10; 32);
4 (5; 14); 5 (15; 39)
Age (years) 55.8±11.9
Gender (F; M) 14; 17
Weight (kg) 77.0±16.2
Gland weight (mg) 647±2.40 (n=54)
Pi (mmol/l) 1.00±0.27 (hypo/normal
(n=16));
0.70–1.50
2.14±0.79 (hyper (n=13))
Ca (mmol/l) 2.45±0.05 (normal (n=4)); 2.15–2.50
2.76±0.16 (hyper (n=27))
PTH (pmol/l) 81.9±58.4 (n=29) 1.26–7.58
Creatinine (mmol/l) 310±179 (F); 412±298 (M) 68.0–98.0 (F);
78.0–123 (M)
ALP (mkat/l) 6.69±10.4 1.80–7.20
Etiology GN (n=11); PCKD (n=5);
DN (n=4); HNS (n=2); PN
(n=2); V (n=1); other (n=6)
Abbreviations: ALP, alkaline phosphatase; CKD, chronic kidney disease; DN, diabetic
nephropathy; F, female; GN, glomerulonephritis; HNS, hypertonic nephrosclerosis;
M, male; PCKD, polycystic kidney disease; Pi, inorganic phosphate; PN, pyelone-
phritis; PTH, parathyroid hormone; sHPT, secondary hyperparathyroidism; V,
vasculitis. The values are presented as arithmetic mean±s.d., except for the
tumor weight (geometric mean±multiplicative s.d.). The glomerular filtration
rate values were calculated according to the four-variable Modification of
Diet in Renal Disease Study equation: Glomerular filtration rate (ml/min per
1.73m2)=175 (sCr; mg/dl)(1.154) age(0.203) (0.742 if female) (1.212 if African
American).32 No measurements of endogenous 25-hydroxycholecalciferol, 1,25-
dihydroxyvitamin D3, or fibroblast growth factor were carried out because of
lack of serum samples. Conversion factors are: calcium (mmol/l) 4.0=(mg/dl); Pi
(mmol/l) 3.1=(mg/dl); PTH (pmol/l) 9.5=(ng/l); creatinine (mmol/l)/88.4=(mg/dl).
Total calcium was corrected for albumin level: calcium (mmol/l)–{0.018 [(albumin;
g/l)–42]}.
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Figure 4 | Fibroblast growth factor receptor 1 (FGFR1) expression in relation to renal function and Klotho. (a) Left: mean parathyroid FGFR1
mRNA levels were positively associated with log glomerular filtration rate (GFR) (n¼ 31, r¼ 0.50, Po0.01; transplanted n¼ 21, r¼ 0.53, Po0.05).
Gray dots represent the four patients from whom only one gland was available (if these are excluded: n¼ 27, r¼ 0.52, Po0.01). Middle: a decline in
glandular FGFR1 mRNA levels was evident when comparing between chronic kidney disease (CKD) stages (n¼ 3/32/14/39, **Po0.01, ***Po0.001
versus stage 5). Error bars represent the 5th and 95th percentiles, and dots represent outliers. Right: log glandular levels of FGFR1 correlated
positively with the corresponding levels of Klotho (n¼ 88, r¼ 0.30, Po0.01; transplanted n¼ 61, r¼ 0.32, Po0.05; or mean values: n¼ 31, r¼ 0.56,
Po0.01; transplanted n¼ 21, r¼ 0.53, Po0.05). (b) Left: mean FGFR1 mRNA levels correlated negatively with serum inorganic phosphate (Pi)
(n¼ 29, r¼0.51, Po0.01; transplanted n¼ 20, r¼0.59, Po0.01). Gray dots represent the four patients from whom only one gland was available
(if these are excluded: n¼ 25, r¼0.53, P¼ 0.01). Right: mean FGFR1 mRNA levels correlated negatively with log serum parathyroid hormone
(PTH) (n¼ 29, r¼0.46, Po0.05; transplanted n¼ 19, r¼0.53, Po0.05). Gray dots represent the four patients from whom only one gland was
available (if these are excluded: n¼ 25, r¼0.50, Po0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 5 |Klotho regulation by calcium, active vitamin D3 compounds, and fibroblast growth factor 23 (FGF23(R176Q)) in cultured
bovine parathyroid cells. (a) Vitamin D3 analog EB1089 (left) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; right) dose-dependently stimulated
Klotho mRNA level, whereas (b) FGF23(R176Q) treatment decreased Klotho expression at 200 pg/ml. (c) Treatment with FGF23(R176Q) in
combination with EB1089 not only blunted (Po0.001) the stimulating effect of the latter (Po0.01), but also suppressed Klotho mRNA level as
compared with control (Ctrl)-treated cells (Po0.001). The effect of the same combination did not differ from the effect of FGF23(R176Q) alone
(P40.05). FGF23(R176Q) and calcium did not suppress Klotho any further (P40.05) than calcium treatment alone (Po0.001). However, the same
combination induced a slightly stronger suppression (Po0.01) in comparison with FGF23(R176Q) alone (Po0.001). Addition of calcium
induced further suppression of Klotho as compared with combined EB1089 and FGF23(R176Q) as well (Po0.001). The concentrations used
were 4 mmol/l calcium, 2000 pg/ml FGF23(R176Q), and 107 mol/l EB1089. All graphs show effects observed after 24 h treatment of bovine
parathyroid cells in vitro (mean±s.e.m., n¼ 3–4 (1,25(OH)2D3: n¼ 2)). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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further stimulated FGFR1 expression (Figure 6b). Similarly,
FGF23(R176Q) and EB1089 combined had a stronger
stimulatory effect than EB1089 alone (Po0.001; Figure 6b).
Finally, calcium and FGF23(R176Q) together stimulated the
FGFR1 expression less effectively in the presence of EB1089
(Po0.01; Figure 6b).
DISCUSSION
An overall decreased expression of Klotho and FGFR1 in
parathyroid glands of CKD patients has been described
recently.17–19 In our cohort despite of varying expression in
the analyzed secondary hyperplastic parathyroid glands, both
Klotho and FGFR1 expression levels were found to be
positively correlated to renal function and significantly
decreased over CKD stages.
The decrease in parathyroid Klotho/FGFR1 level after
progression of CKD may be due to several causes. It may in
part reflect an intrinsic glandular defect, as the development
of parathyroid hyperplasia parallels the decline in renal
function and is more likely to occur in late CKD. This would
be analogs to the reduced parathyroid expression of VDR and
calcium-sensing receptor, which is observed at later stages of
CKD in parallel with glandular nodularity and reduced
sensitivity to the suppressive effects of 1,25(OH)2D3 and
calcium.20–22 A reduction in Klotho/FGFR1 expression could
be a temporal event that coincides with hyperplasia
development. It is however important to emphasize that
these two pathways, and especially the calcium/calcium-
sensing receptor pathway, are of major importance in the
rapid and (normally) very effective PTH regulation,23,24 and
that the FGF23/FGFR1/Klotho pathway may have a smaller,
yet unexplored and contributing role in sHPT.
Alternatively, the reduction in Klotho levels may rather be
a consequence of dynamic biochemical changes occurring in
CKD. This is supported by our bovine in vitro data, showing
that Klotho was suppressed by FGF23 and calcium, but
stimulated by active vitamin D3 compounds. Indeed, a
majority of our patients were hypercalcemic. In concert, CKD
patients suffer from gradually increasing serum FGF23 and
decreasing 1,25(OH)2D3 levels in parallel with declining renal
function.14,25 Unfortunately, because of lack of serum, we
were unable to determine the 1,25(OH)2D3 and FGF23 levels
of our patients. This would have been enlightening, especially
because of the fact that serum Pi inversely correlated with
Klotho expression, although Pi did not regulate Klotho
expression in our cell models. Thus, in this context serum Pi
may just be a marker of higher FGF23 or lower 1,25(OH)2D3
levels. The lack of response in our bovine cell model may
be explained by the fact that intact parathyroid tissue
architecture is required in order for extracellular Pi to exert
its effects,26 or for a possible post-transcriptional regula-
tion.27 Maintenance of the tissue architecture may not be as
necessary in hyperplastic cells, as Pi did regulate the
expression of FGFR1 in the cultured parathyroid cells of a
uremic patient.
Pathophysiology of hyperparathyroidism might be differ-
ent in kidney transplant recipients compared with CKD
patients undergoing dialysis. Although not statistically
significant, there was a tendency for Klotho and a somewhat
stronger tendency for FGFR1 mRNA expression to be higher
in transplanted patients. This suggests that the levels of the
receptor and its coreceptor may improve by an increase in
GFR that may accompany a kidney transplant. The issue
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Figure 6 |Klotho and fibroblast growth factor receptor 1
(FGFR1) regulation by calcium (Ca), active vitamin D3
compounds, FGF23(R176Q) (F), and inorganic phosphate (Pi)
in cultured hyperplastic parathyroid cells from a chronic
kidney disease patient. (a) Klotho mRNA level was mainly
unaffected after 24 h of treatment with various agents at the
given concentrations. Ca was the only single agent that had an
inhibitory effect on Klotho compared with control (Ctrl) treatment
(Po0.05). Treatment with FGF23(R176Q), EB1089 (EB), and 1,25-
dihydroxyvitamin D3 did not alter the Klotho expression level
(P40.05). The suppressive effect of Ca was partially blunted in the
presence of FGF23(R176Q) (Po0.05). Ca, EB1089, and
FGF23(R176Q) together induced a slightly stronger suppression
than combinations of Ca and FGF23(R176Q) (Po0.05), or EB1089
and FGF23(R176Q) (Po0.01) did. The triple combination was the
only treatment other than Ca that suppressed Klotho in
comparison with control treatment (Po0.05). (b) Single treatment
with FGF23(R176Q), 1,25-dihydroxyvitamin D3, and Pi increased
FGFR1 transcript level (Po0.05), whereas Ca and EB1089 did not
reach the significance level (P40.05). Ca and FGF23(R176Q) were
a more effective inducer in combination than separately (Po0.05),
and similarly, combined treatment with FGF23(R176Q) and
EB1089 was more stimulatory than each of the two single
treatments alone (Po0.001). The induction of FGFR1 by combined
Ca and FGF23(R176Q) was stronger when EB1089 was omitted
(Po0.01). The concentrations used were 4 mmol/l Ca, 2000 pg/ml
FGF23(R176Q), 107 mol/l EB1089, 107 mol/l 1,25-
dihydroxyvitamin D3, and 4 mmol/l Pi. Effects observed after 24 h
of treatment of secondary hyperplastic parathyroid cells in vitro
are shown (mean±s.e.m., n¼ 3). GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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would need to be investigated in a larger cohort. The effect of
treatment by immunosuppressive agents on parathyroid
function should be investigated further.
Because Klotho is a specific FGF-receptor co-factor for
FGF23,5 it is likely that parathyroid glands with a reduced
Klotho level do not adequately respond to the inhibitory
action of FGF23 on PTH secretion.10,11 This is in agreement
with what is observed in vivo, that is, high FGF23 levels are
paralleled by high PTH levels.14 Although we did not
previously observe any major effects of FGF23 on parathyroid
cell proliferation or apoptosis in short-term in vitro
culturing,10 we cannot rule out the possibility that FGF23
may be implicated in cell growth and division in the long-
term in vivo through unknown mechanisms. Therefore,
reduced Klotho expression could impair the ability of FGF23
to control cell growth and thereby contribute to the
development of hyperplasia. On the other hand, the declining
parathyroid Klotho expression and the accelerating PTH
levels that occur in progressing CKD, again indicate that PTH
secretion can occur through a Klotho-independent mechan-
ism and despite hypercalcemia.16 Indeed, FGF23 may start to
lose its inhibitory influence on PTH even in moderate CKD
with adequate Klotho expression.
In this study, in vitro data provide mechanistic insights
into the regulation of Klotho and may have several
implications for parathyroid FGF23 action in the uremic
milieu. We showed that active vitamin D3 compounds
stimulate Klotho expression in cultured normal (bovine)
parathyroid cells, as has been observed in the kidney.28 Thus,
treatment with active vitamin D3 derivatives may not only be
beneficial in preventing not only sHPT through direct VDR
signaling, but also by enhancing the FGF23/FGFR1/Klotho-
induced suppression. Nevertheless, the stimulatory effect of
EB1089 was blunted in the presence of high calcium or
FGF23, suggesting that administration of active vitamin D3
compounds in CKD might not induce parathyroid Klotho
expression in such settings, not even in the presence of
normal VDR levels. In fact, EB1089 had no effect on either
Klotho or FGFR1 expression in cultured hyperplastic
(human) parathyroid cells, indicating altered sensitivity and
Klotho regulation of the latter. Active vitamin D3 analogs
administered to CKD patients may even interfere with the
FGFR1 stimulation induced by calcium and FGF23, as
suggested by our human in vitro data.
Another important observation from our bovine cell
model was that the degree of Klotho suppression by FGF23
and calcium was similar to that of high calcium alone. High
calcium interfering with FGF23 signaling might translate into
weakened PTH suppression because of emerging hypercalce-
mia later in sHPT.
It is worth mentioning that our normal cell model
originated from 15–20 bovine glands, whereas the uremic cell
model came from three glands of one CKD individual.
Repeated similar experiments, optimally on a mixture of
hyperplastic parathyroid cells from several uremic individuals,
would be valuable. Interpreting and interpolating data from
cell models with such different initial biology should be
carried out with precaution.
We previously discovered that the Klotho expression in
parathyroid adenomas from patients with primary HPT
inversely correlated to serum calcium.16 In this investigation,
we did not find evidence for such a relationship, indicating
that the regulation of parathyroid Klotho differs between
primary HPT and sHPT and involves factors other than
calcium. This is not surprising given the different etiology,
tissue heterogeneity, and the more prominent derangements
in mineral metabolism in sHPT related to CKD.
In summary, parathyroid Klotho and FGFR1 levels
decrease with declining renal function in CKD patients. This
may be related to an intrinsic glandular defect, although our
data suggest biochemical changes related to CKD, such as
hypercalcemia, low 1,25(OH)2D3, and high FGF23 levels, to
be a probable cause. This may explain the co-occurrence of
high circulatory FGF23 and PTH levels, and the failure of
FGF23 to prevent PTH hypersecretion in late CKD.
MATERIALS AND METHODS
Patients
The patients included had undergone surgical parathyroi-
dectomy between 1998 and 2008. Inclusion criteria were
access to at least one frozen parathyroid tissue sample and a
GFR o90ml/min per 1.73m2. A total of 21 patients were
kidney recipients (4 of them repeated the operation once or
twice), and parathyroidectomy was performed at least 1 year
after the kidney transplantation. One patient underwent
partial surgical parathyroidectomy twice with a 3.5-years
delay and was regarded as two distinct patients with different
biochemistries. In all, 15 patients were on phosphate binders,
14 were treated with active vitamin D3 derivatives (Etalpha
(n¼ 13) or Rocaltrol (n¼ 1)) and two patients received daily
calcimimetics (Mimpara) daily before surgery. Serum
calcium, albumin, Pi, PTH, creatinine, and alkaline phos-
phatase were measured according to standard techniques at
the Department of Clinical Chemistry, Uppsala University
Hospital (Table 1). Informed consent was obtained from all
participants and the procedure was in accordance with the
institutional ethical committee at Uppsala University.
Bovine parathyroid cells in vitro
Primary bovine parathyroid cells were isolated and cultured
according to previous descriptions. Conditioned serum-free
FGF23(R176Q)-containing Dulbecco’s modied Eagle’s med-
ium medium was produced as described earlier. Cells were
treated in triplicates/quadruplicates (if not stated otherwise)
with: control medium,10 also used as diluent, FGF23
(R176Q), calcium, Pi, active vitamin D3 analog EB1089,
29
1,25(OH)2D3, and PTH, as well as FGF23(R176Q) in combi-
nations with calcium and EB1089. The EB1089 analog is a 10
times more potent PTH inhibitor than 1,25(OH)2D3.
29
All treatment media contained the same percentage of
ethanol (EB1089 diluent) and ddH2O (calcium and Pi
diluent). The experiments were repeated 1–3 times.
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Human hyperplastic parathyroid cells in vitro
Three glands from a female patient with GFR at 6.32ml/min
per 1.73m2 were excised, collagenase treated and subjected to
treatments as described above. The biochemical status of the
patient at the time of surgery was: 2.36mmol/l (albumin-
corrected) calcium, 2.20mmol/l Pi, 112 pmol/l PTH, 26400
pg/mL intact FGF23 measured by enzyme-linked immuno-
sorbent assay from Kainos Laboratories, Tokyo, Japan30 and
588 mmol/l creatinine. The patient was a renal transplant
recipient who had returned to dialysis because of allograft
rejection.
Quantitative real-time polymerase chain reaction
RNA extraction and complementary DNA synthesis was
carried out as described before.10,16 Exon-specific primers
were designed and the amplicons were confirmed by
sequencing analysis. Semiquantitative reverse transcriptase-
polymerase chain reaction using SYBR Green was carried out
as described before.10 Each sample is presented as a ratio
between relative Klotho and glyceraldehyde 3-phosphate
dehydrogenase start quantity means, representing each gland
(n¼ 88). An average of all analyzed glands of a patient
represents mean Klotho expression (n¼ 31). The relative
gene expression from the in vitro experiments was calculated
according to the comparative Ct method (2
DDCt ) by Livak
and Schmittgen.31 FGFR1 gene expression was measured in
duplicates with a Taqman assay (Applied Biosystems Inc.,
Foster City, CA, USA; Table 2).
Immunohistochemistry
Protein levels were analyzed by IHC according to standard
frozen tissue protocols. The antibodies used were polyclonal
goat anti-Klotho antibody (Santa Cruz Biothechnology Inc.,
CA, USA; cat. no. sc-22220; 1:7 dilution); monoclonal mouse
anti-Ki67 antibody (Dako Denmark A/S, Glostrup, Denmark;
cat. no. M7240; 1:100 dilution) and monoclonal mouse anti-
VDR antibody (Santa Cruz; cat. no. sc-13133; 1:650
dilution). A consecutive section from one gland was used
each time as a negative control (without primary antibody).
The sections were analyzed twice and each obtained an IHC
score (0.0/0.5/1.0/1.5/2.0/2.5/3.0) as a representative of the
whole section. The intensity of the different protein levels was
compared both metrically by using the IHC scores, as well as
by studying diffuse tissue/nodule boundaries of consecutive
series of individual sections. One section per gland (a total of
42 sections) was used for microscopic determination of
glandular nodularity. Sections were counterstained with
Mayer’s hematoxylin for visualization of the nuclei.
Statistical analyses
GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA,
USA) and Statistica 8 (StatSoft Inc., Tulsa, OK, USA)
softwares were used for statistical data analyses. Normality
testing of patient biochemistry data by the Shapiro–Wilk
W test, the w-square test, and quantile–quantile and
probability–probability plots revealed a normal distribution
of mean Klotho and mean FGFR1 values, calcium, Pi, and
age. All other parameters were logged. Unpaired t-test or
analysis of variance was used for comparison between
independent groups. Univariate, parametric correlation
(Pearson) analysis was applied, except in correlation analyses
carried out on IHC scores, wherein non-parametric Spear-
man’s correlation analyses were used instead. Values are
presented as arithmetic means±s.d. in the text and in Table 1
and as arithmetic means±s.e.m. in the figures, if not stated
otherwise. A P-value of o0.05 was considered statistically
significant.
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